Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 9:00 a.m. PT / 12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will review Kymera’s clinical progress and anticipated 2026 milestones.
A live webcast of the presentation and Q&A will be available under “News and Events” in the Investors section of the company website at www.kymeratx.com, with a replay and archived presentation available after the event.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, KYMR gained 1.45%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $78M to the company's valuation, bringing the market cap to $5.47B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KYMR slipped 0.48% while key biotech peers were mostly down, including CRNX -12.4%, MLTX -5.17%, and APLS -3.68%, with SRRK +1.02% a notable gainer. Moves appear more stock-specific than a uniform sector reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Equity offering close | Negative | -2.3% | Closed upsized public offering with full underwriters’ option exercise. |
| Dec 11 | Regulatory designation | Positive | -2.3% | FDA Fast Track designation for KT-621 in atopic dermatitis. |
| Dec 09 | Equity offering pricing | Negative | -7.9% | Priced upsized public offering of 7,000,000 shares at $86.00. |
| Dec 08 | Proposed equity raise | Negative | +41.5% | Proposed $500.0M common stock offering with underwriter option. |
| Dec 08 | Clinical trial results | Positive | +41.5% | Reported positive BroADen Phase 1b KT-621 data in AD patients. |
Recent news included major positive KT-621 clinical data with strong share gains, while financing-related announcements and Fast Track designation saw mixed to negative price reactions.
Over the last month, Kymera reported positive BroADen Phase 1b data for KT-621 and a subsequent FDA Fast Track designation, alongside multiple equity offerings totaling hundreds of millions in gross proceeds. Clinical news on Dec 8, 2025 and the proposed offering the same day both saw +41.55% moves, while later pricing and closing of the upsized offering on Dec 9–11, 2025 coincided with declines. Today’s conference presentation fits into this cadence of showcasing progress after significant clinical and financing milestones.
Market Pulse Summary
This announcement highlights Kymera’s planned presentation at the J.P. Morgan Healthcare Conference on January 13, 2026, where management intends to review recent progress and 2026 milestones. In the months before this, KT-621 delivered positive Phase 1b data and received FDA Fast Track designation, while the company also executed sizable equity offerings. Investors tracking this story may focus on how conference commentary frames KT-621 development plans and capital deployment following these recent financings and clinical results.
AI-generated analysis. Not financial advice.
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company’s progress and anticipated milestones for 2026.
A live webcast of the presentation and Q&A session will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and the presentation will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When will Kymera Therapeutics (KYMR) present at the J.P. Morgan Healthcare Conference in 2026?
Who will present for Kymera (KYMR) at the January 13, 2026 J.P. Morgan conference?
How can investors watch Kymera Therapeutics (KYMR) presentation on January 13, 2026?
What will Kymera (KYMR) cover in its January 13, 2026 J.P. Morgan presentation?
Will Kymera (KYMR) make presentation materials available after the January 13, 2026 event?
